Disease · MONDO_0005002

chronic obstructive pulmonary disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic obstructive pulmonary disease. Diseases, record MONDO_0005002. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005002

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic obstructive pulmonary disease; Open Targets
Open Targets ID: MONDO_0005002; Open Targets
Other names: Airflow Obstruction, Chronic, Airflow Obstructions, Chronic, CAFL - Chronic airflow limitation, CAL - Chronic airflow limitation, CAO - Chronic airflow obstruction, CHRONIC OBSTRUCTIVE AIRWAY DIS, CHRONIC OBSTRUCTIVE LUNG DIS, CHRONIC OBSTRUCTIVE PULM DIS, COAD, COAD - Chronic obstructive airways disease, COLD, COLD - Chronic obstructive lung disease, COPD, COPD - Chronic obstructive pulmonary disease, COPD NOS, Chronic Airflow Obstruction, Chronic Airflow Obstructions, Chronic airflow limitation, Chronic airway disease, Chronic airway obstruction, Chronic irreversible airway obstruction, Chronic obstructive lung disease, NEC, Chronic obstructive lung disease, NOS, Chronic obstructive pulmonary disease NOS, Chronic obstructive pulmonary disease finding, Chronic obstructive pulmonary disease finding (finding), Dops, PULM DIS CHRONIC OBSTRUCTIVE, Pulmonary Disease, Chronic Obstructive, chronic airway obstruction, NEC in ICD9CM_2006, chronic airway obstruction, not elsewhere classified, chronic obstructive airway disease, chronic obstructive airways disease, chronic obstructive airways disease NOS, chronic obstructive airways disease NOS (disorder), chronic obstructive lung disease, chronic obstructive lung disease (disorder), chronic obstructive lung disease [Ambiguous], chronic obstructive pulmonary disease (COPD), chronic obstructive pulmonary disease and allied conditions, disease (COPD), chronic obstructive, obstructive lung disease, chronic, obstructive pulmonary disease (COPD), chronic, pulmonary disease (COPD), chronic obstructive; Open Targets
Disease Ontology: DOID:3083; Disease Ontology
MeSH: D029424; MeSH
NCI Thesaurus: C3199; NCI Thesaurus
Highest stage of its drugs: Approval, for 44 of its 328 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs328

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TIOTROPIUM	CHEMBL1900528	Small molecule	Approval	TTD	177	176	176	Drugs and targets
FORMOTEROL FUMARATE	CHEMBL3989798	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	111	99	97	Drugs and targets
SALMETEROL	CHEMBL1263	Small molecule	Approval	TTD	91	89	87	Drugs and targets
GLYCOPYRRONIUM BROMIDE	CHEMBL1201027	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	107	88	84	Drugs and targets
FORMOTEROL	CHEMBL1256786	Small molecule	Approval	EMA Human Drugs	93	83	83	Drugs and targets
INDACATEROL	CHEMBL1095777	Small molecule	Approval	EMA Human Drugs and TTD	88	81	80	Drugs and targets
BUDESONIDE	CHEMBL1370	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	91	80	74	Drugs and targets
VILANTEROL	CHEMBL1198857	Small molecule	Approval	EMA Human Drugs and TTD	81	74	73	Drugs and targets
FLUTICASONE PROPIONATE	CHEMBL1473	Small molecule	Approval	DailyMed	76	65	56	Drugs and targets
TIOTROPIUM BROMIDE	CHEMBL3545181	Small molecule	Approval	DailyMed and PMDA	72	64	64	Drugs and targets

1 to 10 of 328

See all 328 drugs

Targets232

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB2	Adrenergic receptor	32	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor	23	Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
NR3C1	Glucocorticoid receptor	19	Glucocorticoid receptor agonist; Glucocorticoid receptor modulator	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
PDE4A	Phosphodiesterase 4	11	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	11	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	11	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	11	Phosphodiesterase 4 inhibitor	Approval	https://conductscience.org/library/genes/5144	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor	8	Muscarinic acetylcholine receptor M2 antagonist; Muscarinic acetylcholine receptor antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1129	Drugs and targets
ADRB1	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/153	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor	6	Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1128	Drugs and targets

1 to 10 of 232

See all 232 targets

Trials1,135

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 26 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04926233	Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study		1,371,146	2021-07-20	Pulmonary Disease, Chronic Obstructive	OLODATEROL, TIOTROPIUM BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT01331694	Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)		76,130	2011-04-08	Pulmonary Disease, Chronic Obstructive	FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE	Its record names the disease	ClinicalTrials.gov
NCT04138758	Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS		42,953	2020-11-30	COPD	OLODATEROL, TIOTROPIUM BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT04184297	Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy		27,190	2020-11-30	Pulmonary Disease, Chronic Obstructive	OLODATEROL, TIOTROPIUM	Its record names the disease	ClinicalTrials.gov
NCT01387178	Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease		22,223	2011-10-28	Pulmonary Disease, Chronic Obstructive	FLUTICASONE PROPIONATE, TIOTROPIUM BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT05393245	Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data		19,467	2024-12-04	Pulmonary Disease, Chronic Obstructive	OLODATEROL, TIOTROPIUM	Its record names the disease	ClinicalTrials.gov
NCT01126437	Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease	Phase 3	17,183	2014-06-20	Pulmonary Disease, Chronic Obstructive	TIOTROPIUM	Its record names the disease	ClinicalTrials.gov
NCT05402020	Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan		17,018	2024-08-09	Pulmonary Disease, Chronic Obstructive	OLODATEROL, TIOTROPIUM	Its record names the disease	ClinicalTrials.gov
NCT01313676	Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease	Phase 3	16,568	2016-08-09	Pulmonary Disease, Chronic Obstructive	FLUTICASONE FUROATE, VILANTEROL	Its record names the disease	ClinicalTrials.gov
NCT05127304	A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol		11,316	2023-11-13	Pulmonary Disease, Chronic Obstructive	FLUTICASONE FUROATE, OLODATEROL, TIOTROPIUM BROMIDE, UMECLIDINIUM, VILANTEROL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,135

See all 1,135 trials

Comparisons in its trials417

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tiotropium + Olodaterol Cohort - Propensity Score Matched vs Inhaled Corticosteroids (ICS) + Long-acting ß2 Agonists (LABA) Cohort - Propensity Score Matched: Number of Subjects With Event First Moderate or Severe COPD Exacerbations After Index Date	424 of 3,752	375 of 3,752	7,504	NCT05402020	Trial comparisons
Tiotropium + Olodaterol Cohort - Propensity Score Matched vs Inhaled Corticosteroids (ICS) + Long-acting ß2 Agonists (LABA) Cohort - Propensity Score Matched: Number of Subjects With Event First Hospitalization for Community-acquired Pneumonia After Entry	11 of 3,752	11 of 3,752	7,504	NCT05402020	Trial comparisons
Tiotropium + Olodaterol Cohort - Propensity Score Matched vs Inhaled Corticosteroids (ICS) + Long-acting ß2 Agonists (LABA) Cohort - Propensity Score Matched: Number of Subjects With Event Triple Therapy Escalation After Index Date	122 of 3,752	153 of 3,752	7,504	NCT05402020	Trial comparisons
Tiotropium vs Salmeterol: serious adverse events	545 of 3,707	606 of 3,669	7,376	NCT00563381	Trial comparisons
FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation	200 of 1,078	674 of 2,923	4,001	NCT01337336	Trial comparisons
Tiotropium vs Placebo: serious adverse events	342 of 1,952	336 of 1,965	3,917	NCT00387088	Trial comparisons
Tiotropium vs Placebo: Number of Patients With at Least One Hospitalisation for a COPD Exacerbation	161 of 1,939	198 of 1,953	3,892	NCT00387088	Trial comparisons
Tiotropium vs Placebo: Number of Patients With at Least One COPD Exacerbation	685 of 1,939	842 of 1,953	3,892	NCT00387088	Trial comparisons
Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) - on Study Analysis	69 of 1,791	76 of 1,798	3,589	NCT01966107	Trial comparisons
Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) or Other Serious Cardiovascular Events of Interest - On-study Analysis	168 of 1,791	160 of 1,798	3,589	NCT01966107	Trial comparisons

1 to 10 of 417

See all 417 comparisons in its trials

Papers from its trials817

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39529298	RESULT	1	PubMed
39458663	RESULT	1	PubMed
39219564	RESULT	1	PubMed
39046133	RESULT	1	PubMed
38803412	RESULT	1	PubMed
38490779	RESULT	1	PubMed
38435125	RESULT	1	PubMed
38108968	RESULT	1	PubMed
38074132	RESULT	1	PubMed
38055196	RESULT	1	PubMed

1 to 10 of 817

See all 817 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005002

GET https://conductscience.org/api/diseases/v1/MONDO_0005002/drugs?page=2

API reference For AI assistants